Clinical trials: Dengue Fever
Dengue
A Cohort Study to Determine the Incidence of Dengue Fever and to Build Capacity for Dengue Vaccine Trials in Dengue-endemic Regions of South Asia
The purpose of this study is to determine the incidence of dengue fever and to build capacity for dengue vaccine trials in dengue-endemic regions of South Asia.
- Trial name
- NCT02570152
- Testing
- Blood sample collection
- Where
- Sri Lanka
- Volunteers
- 2,004 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Dengue Fever, Dengue Hemorrhagic Fever
A Study of Two Doses of WRAIR Dengue Vaccine Administered Six Months Apart to Healthy Adults and Children
The purpose of this study is to evaluate the safety and effectiveness of two different formulations of an investigational dengue vaccine (T-DEN) against a placebo vaccine when two doses are given six months apart to adults and…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Dengue Shock Syndrome
- Trial name
- NCT00468858
- Testing
- T-DEN-Post-Transfection F17, T-DEN-Post-Transfection F19
- Where
- 11 sites in Puerto Rico
- Volunteers
- 636 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue Fever
A Study of Dengue Tetravalent Vaccine (TDV) in Adults (Age 45 to 60 and >60 to 79 Years)
Dengue fever is caused by an infection with the dengue virus. Vaccination with Dengue Tetravalent Vaccine (TDV) can help prevent dengue fever.
- Trial name
- NCT06579755
- Testing
- TDV
- Where
- 7 sites in Argentina, Brazil and 2 more
- Volunteers
- 800 people, healthy volunteers welcome
- Sponsor
- Takeda
Virus
Genetic Determinants of the Antiviral Immune Response in Oceanian Populations
Oceania's populations, including Melanesians, are paying a heavy price for dengue fever, which has been circulating actively in the region since the Second World War.
- Trial name
- GEDIPOP (NCT06432855)
- Testing
- Blood collection, saliva collection
- Where
- New Caledonia
- Volunteers
- 220 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue Virus
Comparison of Tetravalent Dengue Virus Purified Inactivated Vaccine and Tetravalent Dengue Virus Live Attenuated Vaccine
This study is a Phase 1, randomized, open-label study of the prime-boost vaccine candidates given in the prime-boost regimen previously demonstrated to have a high level of immunogenicity and immune durability: Day 0 prime (PIV)…
- Trial name
- NCT03141138
- Testing
- TDENV-PIV, TDENV-LAV F17
- Where
- United States
- Volunteers
- 40 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Dengue
Safety of and Immune Response of a 2-dose Regimen of rDEN1delta30 Dengue Virus Vaccine
Dengue fever, caused by dengue viruses, is a major health problem in tropical and subtropical regions of the world. The purpose of this study is to evaluate the safety of and immune response to a 2-dose regimen of a new…
- Trial name
- NCT00473135
- Testing
- rDEN1delta30
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue
Prospective Study of Infant Dengue
Dengue is a common disease and a major health concern in the Philippines. Dengue is caused by a virus transmitted from the bite of an infected mosquito.
- Trial name
- NCT00377754
- Where
- Philippines
- Volunteers
- 20,000 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Dengue, Dengue Hemorrhagic Fever
Study of a Booster Injection of Pentaxim™ Vaccine Administered With Dengue Vaccine in Healthy Toddlers
The aim of the study was to assess whether the second CYD dengue vaccination could be administered concomitantly with the booster vaccination of a pediatric combination vaccine (Pentaxim™) during the same day visit but in 2…
- Trial name
- NCT01411241
- Testing
- Live, attenuated, recombinant dengue serotype 1, 2, 3, and 4 virus, DTaP IPV//Hib vaccine, Measles, mumps, and rubella vaccine
- Where
- 4 sites in Mexico
- Volunteers
- 720 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue Fever
A Phase I/II Trial of a Tetravalent Live Attenuated Dengue Vaccine in Flavivirus Antibody Naïve Children
To assess the safety, reactogenicity and immunogenicity of two doses of the dengue vaccine in Flavi-virus antibody-naive children between 6 and 9 years of age.
- Trial name
- NCT00384670
- Testing
- Dengue Vaccine Formulation 17, Licensed Japanese Encephalitis (JE) Vaccine
- Where
- Thailand
- Volunteers
- 7 people, healthy volunteers welcome
- Sponsor
- U.S. Army Medical Research and Development Command
Zika Virus Infection
Safety and Immunogenicity of BBV121
To evaluate the safety, tolerability, and immunogenicity of two-doses of three-sequentially escalating cohort (2.5 µg, 5 µg and 10 µg) of BBV121 (purified inactivated adsorbed Zika virus vaccine) compared with Placebo (Alum).
- Trial name
- Zika (NCT04478656)
- Testing
- BBV121
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Bharat Biotech International Limited
Dengue Fever
Clinical Specimens Testing Program of Dengue Antigen Detection Reagents
Dengue virus serological reagent, included antigen and antiserum, is a serum test for identification of serum antibodies to dengue virus.
- Trial name
- NCT01917422
- Where
- Taiwan
- Volunteers
- 195 people, healthy volunteers welcome
- Sponsor
- Kaohsiung Medical University Chung-Ho Memorial Hospital
Zika Virus, Pregnancy Related
ZIKAlliance Pregnant Women Cohort
The aim of this proposal is to evaluate the causal relationship between Zika virus (ZIKV) infections in pregnancy and congenital malformations.
- Trial name
- ZIKAlliancePW (NCT03188731)
- Where
- 14 sites in Bolivia, Brazil and 5 more
- Volunteers
- 3,852 people, healthy volunteers welcome
- Sponsor
- University of Heidelberg Medical Center
Dengue, Dengue Fever
Prospective Dengue Seroprevalence Study in 5 to 10 Year-old Children
This is a descriptive prospective community-based seroprevalence study. Primary objective: To determine the prevalence of specific antibodies (immunoglobulin G [IgG]) against dengue in healthy 5 to 10 year-old children in India.
- Conditions
- Dengue, Dengue Fever, Dengue Hemorrhagic Fever
- Trial name
- NCT01477671
- Where
- 4 sites in India
- Volunteers
- 667 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Zika Virus
Evaluation of the Protective Efficacy of TV003 or Previous Zika Infection Against Infection With ZIKV-SJRP Challenge Compared to DENV and ZIKV-naïve Controls Against Infection With ZIKV-SJRP Challenge
Zika virus (ZIKV) is an illness people can get from mosquitoes. The infection is generally mild with symptoms that include a fever, rash, red eyes, and joint pain, though most of those infected have no symptoms.
- Trial name
- NCT06805487
- Testing
- TetraVax-DV-TV003 (TV003), Plasmalyte, Challenge virus ZIKV-SJRP/2016-184
- Where
- 2 sites in United States
- Volunteers
- 27 people, healthy volunteers welcome
- Sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
Arbovirus Disease, Zika
Population Immunity AgaiNst mosquitO-borne Diseases in Vanuatu
The Pacific region is facing several emerging and neglected diseases notably mosquito-borne diseases as malaria or arboviroses among which dengue, Ross River, chikungunya and Zika.
- Conditions
- Arbovirus Disease, Zika, Dengue, Ross River
- Trial name
- PIANO (NCT05153018)
- Testing
- Blood collection
- Where
- 4 sites in Vanuatu
- Volunteers
- 1,122 people, healthy volunteers welcome
- Sponsor
- Institut Pasteur
Dengue Fever
Immunogenicity and Safety of Tetravalent Dengue Vaccine Candidate (TDV) in Flavivirus-Naïve and Dengue-Immune Adults
The purpose of this study is to assess the neutralizing antibody response against each dengue serotype post-vaccination.
- Trial name
- NCT03746015
- Testing
- TDV
- Where
- 2 sites in United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Takeda
Dengue Fever, Dengue Hemorrhagic Fever
Immunogenicity and Safety of a Tetravalent Dengue Vaccine Administered Concomitantly or Sequentially With Gardasil®
The aim of the study was to assess the safety and immunogenicity of the CYD dengue vaccine and Gardasil (Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant) when administered concomitantly or…
- Conditions
- Dengue Fever, Dengue Hemorrhagic Fever, Human Papillomavirus Disease
- Trial name
- NCT02993757
- Testing
- CYD Dengue Vaccine, Human Papillomavirus Quadrivalent [Types 6, 11, 16, and 18] Vaccine, Recombinant.
- Where
- 5 sites in Malaysia
- Volunteers
- 528 people, healthy volunteers welcome
- Sponsor
- Sanofi Pasteur, a Sanofi Company
Dengue
Butantan-DV Vaccine in Elderly Populations (DEN-04-IB)
This is a randomized, double-blind (60 -79 years) and open-label (40-59 years), three-arm parallel Phase 3b, multicenter study to evaluate the safety and non-inferiority of the humoral immune response of the Butantan Dengue…
- Trial name
- DEN-04-IB (NCT06891950)
- Testing
- Dengue 1,2,3,4 (attenuated) vaccine
- Where
- 5 sites in Brazil
- Volunteers
- 997 people, healthy volunteers welcome
- Sponsor
- Butantan Institute